AI
SUPN icon

AdvisorShares Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

AdvisorShares Investments’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
27,618
+10,165
+58% +$488K 0.16% 73
2026
Q1 		$902K Sell
17,453
-10,941
-39% -$557K 0.16% 89
2025
Q4 		$1.41M Buy
28,394
+12,869
+83% +$626K 0.24% 57
2025
Q3 		$742K Buy
+15,525
New +$625K 0.12% 91

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

AdvisorShares Investments's SUPN Position: Q2 2026 in Review

AdvisorShares Investments increased its Supernus Pharmaceuticals (SUPN) stake by 58% in Q2 2026, buying an estimated $488K and bringing the position to 27,618 shares worth $1.28M. The position accounts for 0.16% of the portfolio, ranked #73.

AdvisorShares Investments first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.41M in Q4 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • AdvisorShares Investments held 27,618 shares of Supernus Pharmaceuticals worth $1.28M as of Q2 2026.
  • AdvisorShares Investments bought 10,165 Supernus Pharmaceuticals shares in Q2 2026, an estimated $488K.
  • Supernus Pharmaceuticals made up 0.16% of AdvisorShares Investments's portfolio in Q2 2026, its #73 holding.
  • AdvisorShares Investments first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • AdvisorShares Investments's Supernus Pharmaceuticals position peaked at $1.41M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.